Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Zonagen (zona) - good buy? -- Ignore unavailable to you. Want to Upgrade?

To: Don Kelly who wrote (1060)	12/16/1997 11:57:00 PM
From: Bruce Rosen	Read Replies (1) \| Respond to of 7041

Hi Don! I hope you don't mind if I address your question. <<Did Asensio single-handedly cause the stock to tank, or is there something else (fundamentally) going on here?>> Asensio had a lot to do with it, but no he couldn't have done this alone. He had other short sellers with him as well as some who fancy themselves experts who don't have the guts to go public. They are probably jealous of Zonagen's success and IMO, only wish it were they who were involved with this rising young company. This terrible market for tech and biotech stocks hasn't helped and neither has the travails of Vivus, which has its own, unique problems. By the way, I think Vivus is an excellent buy at these levels too. As far as anything fundamental going on, I don't think so! They have $72 million in cash, which is a huge sum for a development stage biotech company. They have strongly statistically significant Phase III studies in hand from a highly reputable testing organization and they have a marketing agreement with Schering-Plough, which has stated publically that they conducted their due diligence and believe in the validity of both Zonagen's patent position and its Phase III results. I hope this helps.